FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma

Following an accelerated approval earlier this year, analysis of data from an ongoing confirmatory trial has shown an increased risk of death with melphalan flufenamide (Pepaxto).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news